Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lyra Therapeutics

13.50
-2.0000-12.90%
Pre-market: 13.590.0900+0.67%06:32 EDT
Volume:572.85K
Turnover:7.79M
Market Cap:17.89M
PE:-0.22
High:14.91
Open:14.88
Low:12.53
Close:15.50
Loading ...

Lyra Therapeutics Is Maintained at Neutral by HC Wainwright & Co.

Dow Jones
·
10 Jun

Refile-Lyra Therapeutics, Inc. : H.c. Wainwright Adjusts Target Price to $16 From $2 to Reflect 1-for-50 Reverse Stock Split (Clarifies PT Is Split Adjusted)

THOMSON REUTERS
·
10 Jun

Lyra Therapeutics target adjusted to $16 from $2 at H.C. Wainwright

TIPRANKS
·
10 Jun

Lyra Therapeutics Unveils Strategic Plans for LYR-210

TIPRANKS
·
09 Jun

Jefferies Sticks to Their Hold Rating for Lyra Therapeutics (LYRA)

TIPRANKS
·
04 Jun

BTIG Keeps Their Hold Rating on Lyra Therapeutics (LYRA)

TIPRANKS
·
03 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Natgas companies, UnitedHealth, Cactus

Reuters
·
03 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Lyra Therapeutics, Church & Dwight, Applied Digital

Reuters
·
02 Jun

Lyra Therapeutics Inc : Jefferies Raises Target Price to $30 From $0.50

THOMSON REUTERS
·
02 Jun

Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings

Benzinga
·
02 Jun

BUZZ-Lyra Therapeutics soars after nasal drug meets trial goals in late-stage study

Reuters
·
02 Jun

Lyra Therapeutics Shares Soar 603% to $34.67 After Rhinosinusitis Drug Meets Main Goal in Late-Stage Study

THOMSON REUTERS
·
02 Jun

Lyra Therapeutics Stock (LYRA) Rockets 530% on Phase 3 Trial Results

TIPRANKS
·
02 Jun

Lyra Therapeutics Shares Soar 563% to $32 Premarket After Rhinosinusitis Drug Meets Main Goal in Late-Stage Study

THOMSON REUTERS
·
02 Jun

Lyra Says Phase 3 Trial of Nasal Implant for Chronic Rhinosinusitis Meets Endpoints

MT Newswires Live
·
02 Jun

Lyra Therapeutics Inc. Unveils Presentation on Innovative Sinonasal Drug Implants for Chronic Rhinosinusitis Treatment

Reuters
·
02 Jun

Why Did Lyra Therapeutics’ Stock Rocket Past 440% in Premarket Today

CoinMarketCap
·
02 Jun

Lyra Therapeutics says ENLIGHTEN 2 trial of LYR-210 met primary endpoint

TIPRANKS
·
02 Jun

Lyra Therapeutics Reports Positive Results From the Enlighten 2 Phase 3 Trial of Lyr-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (Crs)

THOMSON REUTERS
·
02 Jun

Lyra Therapeutics Inc - Lyr-210 Well-Tolerated With Safety Profile Similar to Sham Control

THOMSON REUTERS
·
02 Jun